Hopp til hovedinnhold

Valproat sikkerhetsinformasjon

Sist oppdatert: Sist revidert:

  1. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013 Mar;12(3):244-52. doi: 10.1016/S1474-4422(12)70323-X. Epub 2013 Jan 23. PMID: 23352199 PubMed  
  2. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F; EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011 Jul;10(7):609-17. doi: 10.1016/S1474-4422(11)70107-7. Epub 2011 Jun 5. PMID: 21652013 PubMed  
  3. https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances-0
  4. https://www.ema.europa.eu/en/news/prac-recommends-new-measures-avoid-valproate-exposure-pregnancy
  5. European Medicines Agency. PRAC recommends strengthening the restrictions on the use of valproate in women and girls. 2014. 2016.05.04. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/10/WC500175208.pdf
  6. Perucca P, O'Brien TJ, Eadie M, Vajda FJ. Valproate still has a place in women with epilepsy. Epilepsia. 2015 Jul;56(7):1175-6. doi: 10.1111/epi.13029. No abstract available. PMID: 26149794 PubMed  
  7. European Medicines Agency. New review of valproate use in pregnancy and women of childbearing age. Accessed March 13th 2017 at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substances/human_referral_prac_000066.jsp&mid=WC0b01ac05805c516f.
  8. Tomson T. Commentary: Valproate in the treatment of epilepsy in women and girls: The need for recommendations. Epilepsia. 2015 Jul;56(7):1004-5. doi: 10.1111/epi.13036. pub 2015 May 23. No abstract available. PMID: 26011322 PubMed  
  9. Johannessen Landmark C, Burns ML, Baftiu A, Farmen AH, Lossius MI, Johannessen SI, Tomson T. Pharmacokinetic variability of valproate in women of childbearing age. Epilepsia. 2017 Oct;58(10):e142-e146. doi: 10.1111/epi.13872. Epub 2017 Aug 22. PMID: 28833045 PubMed  
  10. Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, Kälviäinen R, Trinka E. Epilepsia. 2015 Jul;56(7):1006-19. doi: 10.1111/epi.13021. Epub 2015 May 16. Review. PMID: 25851171 PubMed  
  11. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F; EURAP Study Group. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology. 2015 Sep 8;85(10):866-72. doi: 10.1212/WNL.0000000000001772. Epub 2015 Jun 17. PMID: 26085607 PubMed  
  12. Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016 Dec 1;18(4):367-383. doi: 10.1684/epd.2016.0880. Review. PMID: 27965183 PubMed  
  13. Reimers A, Berg JA, Burns ML, Landmark CJ. Harmonised reference ranges for antiepileptic drugs. Tidsskr Nor Laegeforen. 2017 Jun 26;137(12-13):864-865. doi: 10.4045/tidsskr.17.0392. Print 2017 Jun 27. Norwegian, English. No abstract available. PMID: 28655236 PubMed